CCR5-D32杂合性对HIV-1感染者高效抗逆转录病毒治疗病毒学反应与免疫学反应影响的meta分析  

Effects of CCR5-D32 heterozygosity on virological and immunological responses to highly-active antiretroviral therapy in HIV-1-infected patients: a meta-analysis

作　　者：闻颖[1] 邓宝成[1] 刘沛[1] 

机构地区：[1]中国医科大学附属第一医院传染科,辽宁沈阳110001

出　　处：《中国现代医学杂志》2016年第6期69-74,共6页China Journal of Modern Medicine

摘　　要：目的评价趋化因子受体5-D32（CCR5-D32）杂合性对HIV-1感染者高效抗逆转录病毒治疗病毒学反应与免疫学反应的影响。方法在Pub Med,Web of Science和China Biology Medicine数据库检索,文献收索至2015年10月1日。结果按照入选标准,有11篇文献入选病毒学反应分析,4篇文献入选免疫学反应分析。CCR5-D32杂合性人群病毒学反应较高（O^R=1.24;95%CI=1.15～1.35;P=0.000）,免疫学反应也较高（O^R=1.17,95%CI=1.04～1.31,P=0.009）。病毒学反应亚组分析,在至少1年的观察期以及具有稍高的HIV RNA检测门槛的研究中,CCR5-D32杂合性与较高的病毒学反应具有相关性。由于文献少,免疫学反应分析中无法进行亚组分析。结论 CCR5-D32杂合性人群病毒学反应较高。其与免疫学反应的相关性由于文献偏少仍需进一步证实。Objective To evaluate the effect of C-C chemokine receptor 5-D32（CCR5-D32） heterozygosity of HIV-1-infected patients on the virological and immunological responses to highly-active antiretroviral therapy（HAART）. Methods A literature search on the articles published before October 1, 2015 was conducted in the Pub Med, Web of Science and China Biology Medicine databases. Results Eleven studies on virological response and only four studies on immunological response were eligible for inclusion. Populations with CCR5-D32 heterozygosity had stronger virological（^OR = 1.24;95% CI = 1.15-1.35;P = 0.000） and immunological（^OR = 1.17;95% CI =1.04-1.31;P = 0.009） responses to HAART. There was a significant association between CCR5-D32 heterozygosity and stronger virological response in studies that involved at least one year of observation and a high threshold of detection for HIV RNA. Due to an insufficient number of eligible studies, further subgroup analyses of immunological responses could not be performed. Conclusions Stronger virological response has been found in the populations with CCR5-D32 heterozygosity. The association of CCR5-D32 heterozygosity with immunological response still needs further confirmation.

关 键 词：CCR5-D32杂合性 高效抗逆转录病毒治疗 病毒学反应 免疫学反应 META分析 

分 类 号：R512.91[医药卫生—内科学]